Outcome
| Type |
Measure |
Description |
Time frame |
Safety issue |
| Primary |
Percentage of Participants Categorized Based on Treatments Patterns |
Percentage of participants will be reported categorized based on treatment patterns including use of treatments (yes/no), use of different treatments (pharmacological and non-pharmacological), and use of each type of treatment stratified by type of hospital (public or private centers). |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Percentage of Participants Categorized Based on Different Specialists who Diagnosed Narcolepsy |
|
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Percentage of Participants Categorized Based on Usage of Different Procedures or Tests for the Diagnosis of Narcolepsy |
Percentage of participants will be reported based on clinical history, absence/presence of cataplexy, number of cataplexy attacks, number of sleep-onset REM periods (SOREMPs), absence/presence of apneas and /or Apnea-hypopnea Index (AHI), hipocrexine levels, Epworth Sleepiness Scale (ESS), polysomnogram (PSG), multiple sleep latency test (MSLT) and types of human leucocyte antigen (HLA). |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Time From First Symptom to Diagnosis of Narcolepsy |
|
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Time from Diagnosis of Narcolepsy to First Treatment |
|
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Percentage of Participants Categorized Based on Pharmacological Treatment and Interventions Received in Relation With the Presence of Most Typical Symptoms |
Most typical symptoms will include excessive day time sleepiness, cataplexy, sleep paralysis, and hallucinations. |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Percentage of Participants With Pharmacological Treatments at Each Line |
|
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Sustained Attention to Response Task (SART) |
Behavioral measure of working memory, attention, and impulse/inhibitory control - The Sustained Attention to Response Task (SART) is a computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target (often the digit 3) presented amongst a background of frequent non-targets (0-2, 4-9). After each block, two probe questions are presented in succession. The first asks, "Where was your attention focused during this block of trials?" Participants respond on a 6-point Likert scale, where 1 represents, "on task," and 6, "off task." A second question asks, "How aware were you of where your attention was during this block of trials?" Participants respond on a similar scale, where 1 represents, "aware," and 6, "unaware." |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Maintenance of Wakefulness Test (MWT) |
The MWT is a validated objective measure that evaluates a person's ability to remain awake under soporific conditions for a defined period of time. This tendency to fall asleep is measured via electroencephalography-derived sleep latency. Sleep onset is defined as the first epoch of greater than 15 seconds of cumulative sleep in a 30-second epoch. During each MWT session (1 session equals to [=] 40 minutes), participants will be instructed to sit quietly and remain awake for as long as possible. If no sleep has been observed according to these rules, then the latency is defined as 40 minutes. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake. |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Epworth Sleepiness Scale (ESS) |
ESS is a subjective, self-administered questionnaire to assess daytime sleepiness and consists of 8 items, on a 4-point scale (0-3) ranging from "No chance of dozing" to "High chance of dozing" while engaged in eight different activities. The score can range from 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range. |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Percentage of Participants Categorized Based on Different Non-pharmacological Treatment Approach |
Percentage of participants will be reported based on different non-pharmacological treatment approach assessed through ad-hoc questionnaire including taking short naps, maintaining a regular sleep schedule, avoiding caffeine or alcohol before bed, avoiding smoking especially at night, daily exercise, avoiding large and heavy meals before bedtime, and relaxation before bed. |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Percentage of Participants Categorized Based on Utilization of Direct Healthcare Resource Utilized per Year |
Percentage of participants will be reported based on assessment of type and number of direct healthcare resource utilized per year which include routine monitoring visits (specialists involved, tests conducted, treatment variations), number of emergency visits (specialists involved, tests/procedures conducted, treatment administered), number and duration of hospitalizations and complications derived from narcolepsy. |
From a year before study visit (approximately 24 months) |
|
| Secondary |
Work Productivity and Activity Impairment (WPAI) |
WPAI scores will be used to describe the indirect healthcare resources. It is self-administered 6-item questionnaire (scale of 0-10) which assess the effect of disease on work productivity in the past 7 days obtained for absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity Impairment / disability. Higher scores indicates greater impairment. |
From a year before study visit (approximately 24 months) |
|
| Secondary |
Number of Participants Categorized Based on Occupational Accidents |
Number of participants will be reported based on occupational accidents. Occupational accidents will be assessed through ad-hoc questions for motor vehicle accidents (MVAs) and near miss accidents (NMAs) and will be described through the answer of the two following questions by participants: "Have you had a motor vehicle accident at work during the last years?" and "Have you had a near-miss driving accident during the last year? |
From a year before study visit (approximately 24 months) |
|
| Secondary |
Percentage of Participants Categorized Based on Cost of Direct Healthcare Resources Utilized by Participants per Year |
Percentage of participants will be reported based on costs of following direct healthcare resources will be included: treatment received, routine monitoring visits (specialists and GPs), tests performed, emergency rooms visits, hospitalizations and complications derived from narcolepsy, and unitary costs. |
From a year before study visit (approximately 24 months) |
|
| Secondary |
Health Related Quality of Life (HRQoL) Assessed by European Quality of Life Five Dimension (EQ-5D) Questionnaire |
The EQ-5D questionnaire is a generic instrument for describing and valuing health. It is based on a descriptive system that defines health in terms of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 3 response categories corresponding to no problems, some problems, and extreme problems. The instrument is designed for self-completion, and respondents also rate their overall health on the day of the interview on a 0-100 hash-marked, vertical visual analogue scale (EQ-VAS). Higher score indicates better health state. |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Stigma Scale for Chronic Illness 8-item version (SSCI-8) |
SSCI-8 is a 8 items scale developed to assess internalized and experienced stigma across neurological conditions. It uses a 5-point Likert scale ranging from 1 (never) to 5 (always). |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Treatment Satisfaction of Participants Assessed by Treatment Satisfaction Questionnaire for Medication (TSQM-9) |
TSQM-9, derived from the TSQM-14, is 9-item treatment satisfaction questionnaire for medication as a general measure of satisfaction with treatment. It measures scores on 3 scales: effectiveness scale (questions 1 to 3), the convenience scale (questions 9 to 11) and the overall satisfaction scale (questions 12 to 14). The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Percentages of Participants Based on Most Prevalent Comorbidities and Other Concomitant Disorders Associated With Narcolepsy |
|
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Charlson Comorbidity Index (CCI) |
CCI is a scale to estimate 10-year mortality based on a score from a range of 12 comorbidities, the comorbidity score ranges from 0 to a maximum of 24 points. Higher scores indicate the higher chances of mortality. |
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
| Secondary |
Number of Participants With Adverse Events (AEs) |
|
From a year before narcolepsy diagnosis up to study visit (approximately 24 months) |
|
